New DNA Vaccines Data Have Been Reported by Researchers at University of Cape Town [Human papillomavirus (HPV) type 16 E7 protein bodies cause tumour regression in mice]
By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- New research on Biotechnology is the subject of a report. According to news reporting originating in Rondebosch, South Africa, by NewsRx journalists, research stated, "Human papillomaviruses (HPV) are the causative agents of cervical cancer in women, which results in over 250 000 deaths per year. Presently there are two prophylactic vaccines on the market, protecting against the two most common high-risk HPV types 16 and 18."
The news reporters obtained a quote from the research from the University of Cape Town, "These vaccines remain very expensive and are not generally affordable in developing countries where they are needed most. Additionally, there remains a need to treat women that are already infected with HPV, and who have high-grade lesions or cervical cancer. In this paper, we characterize the immunogenicity of a therapeutic vaccine that targets the E7 protein of the most prevalent high-risk HPV - type 16 - the gene which has previously been shown to be effective in DNA vaccine trials in mice. The synthetic shuffled HPV-16 E7 (16E7SH) has lost its transforming properties but retains all naturally-occurring CTL epitopes. This was genetically fused to Zera ®, a self-assembly domain of the maize.-zein able to induce the accumulation of recombinant proteins into protein bodies (PBs), within the endoplasmic reticulum in a number of expression systems. High-level expression of the HPV 16E7SH protein fused to Zera ® in plants was achieved, and the protein bodies could be easily and cost-effectively purified. Immune responses comparable to the 16E7SH DNA vaccine were demonstrated in the murine model, with the protein vaccine successfully inducing a specific humoral as well as cell mediated immune response, and mediating tumour regression. The fusion of 16E7SH to the Zera ® peptide was found to enhance the immune responses, presumably by means of a more efficient antigen presentation via the protein bodies."
According to the news reporters, the research concluded: "Interestingly, simply mixing the free PBs and 16E7SH also enhanced immune responses, indicating an adjuvant activity for the Zera ® PBs."
For more information on this research see: Human papillomavirus (HPV) type 16 E7 protein bodies cause tumour regression in mice. BMC Cancer, 2014;14():1-15. BMC Cancer can be contacted at: Biomed Central Ltd, 236 Grays Inn Rd, Floor 6, London WC1X 8HL, England. (BioMed Central - www.biomedcentral.com/; BMC Cancer - www.biomedcentral.com/bmccancer/)
Our news correspondents report that additional information may be obtained by contacting M. Whitehead, University of Cape Town, Inst Infect Dis & Mol Med, ZA-7700 Rondebosch, South Africa. Additional authors for this research include P. Ohlschlager, F.N. Almajhdi, L. Alloza, P. Marzabal, A.E. Meyers, I.I. Hitzeroth and E.P. Rybicki (see also Biotechnology).
Keywords for this news article include: Biotechnology, Rondebosch, South Africa, DNA Vaccines, Synthetic Vaccines
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC